Choncept?s scientific innovation is focused on development of new technology to produce chondroitin from fermentation of recombinant bacteria to replace the current chondroitin source of beef and other animal by-products.
A subsidiary of Core Oncology, Mills Biopharmaceuticals, LLC (Mills) manufactures ProstaSeed? Iodine 125 brachytherapy seeds for the treatment of prostate cancer. Mills’ state-of-the-art 25,000 square foot manufacturing facility features highly automated machines and advanced manufacturing systems.
Cosmetic Specialty Labs is skilled in developing high end, prestige skin care products, as well as custom formulated over the counter drugs.
Hyalose specializes in Hyaluronic Acid production and application. The Emergent Technologies Inc. ?Sugar Companies? offer innovative technologies for producing Hyaluronic Acid, heparosan, and chondroitin in a reproducible and safe manner for a variety of medical and aesthetic uses. Hyalose was formed to commercialize unique recombinant technologies for producing Hyaluronic Acid, an important biomolecule for many healthcare and cosmetic applications.
DormaTarg, Inc is a biotechnology company researching and developing therapeutic drugs for cancer recurrence prevention.
GG Companies develops a powerful arthritis rub, a topical herbal gel used to soothe painful areas.
UltraBotanica has developed a patented method to bind curcumin to whey protein, effectively increasing the bioavailability by 15,000x.
The Lupus Multiplex Registry and Repository is finding the genes that cause lupus (also known as SLE or Systemic Lupus erythematosus). It works with families with one or more living lupus patients from across the US, Canada, Puerto Rico and the Virgin Islands, utilizing the genetic link between blood relatives to locate responsible genes.
Cassion Biotech has developed a bio-superior drug delivery system, HEPylation ? System, which uses a patented composition designed to improve the performance of many powerful drug compounds in terms of safety, tolerability, efficacy, and quality.
Otologic Pharmaceutics, Inc. is an organization formed specifically to commercialize promising technologies that address novel pharmacological solutions for hearing and balance health.
Analytical testing laboratory that provides innovative methodologies for greater flexibility and higher throughput for data collection needs.
Cytovance? Biologics adds significant value to biopharmaceutical development programs assisting companies to advance recombinant protein, antibody and cell-based therapeutic products rapidly and cost-effectively from the laboratory bench, through clinical development and to commercial launch in international markets.
Arthrokinex is a comprehensive joint health program that can reduce or eliminate joint pain from osteoarthritis through the healing powers of the patient’s own blood without complications.
Jortan Pharmaceuticals Inc.?(JORTAN) was founded around aspartic protease inhibitors as potential diabetes therapeutics based on technology from the Oklahoma Medical Research Foundation (OMRF).
Ecolab Inc. (Ecolab) develops and markets products and services for the hospitality, foodservice, healthcare and industrial markets.
Astellas is an international pharmaceutical company intensely focused on five key therapeutic areas: cardiology, dermatology, immunology, infectious disease, and urology.
IPS Research Company provides phase 1-4 inpatient and outpatient clinical trials. IPS Research specializes in clinical drug trials dealing with psychiatric disorders, including Depression, Schizophrenia, Bipolar Depression, ADHD, GAD, PTSD, Dementia, Alzheimer?s Disease, Child Depression and a variety of Anxiety Disorders.
Kemmx Corporation is a start-up, biotechnology company pioneering the development and commercialization of targeted analgesics for chronic pain. Their topical analgesic formulations provide long lasting pain relief with minimal side effects.
Tetherex is developing a treatment for inflammatory and thrombotic diseases such as Crohn’s disease. Preclinical studies have shown a positive impact in remission of the disease with evidence of potentially reversing the disease process.
Pure MHC focuses on HLA related immunology tools for vaccine development and immunotherapy validation.
Synereca Pharmaceuticals addresses the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics.